Of those that had therapeutic levels of 6-TGN, 30/42 (71%) were in clinical remission. 7/30 (23%) were in total remission (clinical, biochemical [normal CRP/WCC], endoscopic and histological). 16/30 (53%) were on Azathioprine (AZA), 14/30 (47%) were on mercaptaprine (6MP). 11/30 (37%) were on combined therapy with biologics.

Of those that had non-therapeutic levels of 6-TGN, 19/32 (59%) were in clinical remission. 5/19 (26%) were in total remission. 12/19 (63%) AZA. 7/19 (37%) 6MP. 7/19 (37%) were on combined therapy.

Of those with therapeutic levels of 6-TGN, 12/42 (29%) were not in clinical remission. 6/12 (50%) AZA, 6/12 (50%) 6MP. 8/12 (75%) were on combined therapy with biologics.

Of the cohort that had non-therapeutic levels of 6-TGN, 13/32 (41%) were not in clinical remission. 6/13 (46%) AZA, 7/13 (44%) 6MP. 11/13 (85%) were on combined therapy.

Conclusion: Our study so far suggests that, clinical remission rates were similar (71% vs. 59%) for those who had therapeutic 6-TGN levels and for those who had not. It also shows that even without achieving therapeutic levels of 6-TGN, 59% of patients were still in clinical remission. Our study interestingly highlights that even with therapeutic 6-TGN levels and for those who had not. It also rates were similar (71% vs. 59%) for those who had therapeutic levels of 6-TGN.